Large Molecule Patents
Herceptin is a drug owned by Genentech, Inc.. It is protect by 1 US patents. Given below is the list of those patents along with their expiration dates.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US10808037 | GENENTECH, INC. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
Jul, 2028
(3 years from now) | Active |
Herceptin's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
About Herceptin
Active Ingredients:
Herceptin contains Trastuzumab as an active ingredient
Approval Date:
Herceptin was first approved for market use on 25 Sep, 1998.
Dosage:
Herceptin is available in 2 strengths and the following dosage forms are - For Injection form for Intravenous use.
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 150MG | For Injection | Rx | Intravenous |
| 150MG | For Injection | Rx | Intravenous |
| 420MG | For Injection | Disc | Intravenous |
| 420MG | For Injection | Disc | Intravenous |
| 420MG | For Injection | Rx | Intravenous |